UNSPSC 51123904: Diprafenone

This classification denotes an antiarrhythmic agent with the molecular formula C23H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1P35MD5C1F, chemically known as 1-propanone, 1-(2-(3-((1,1-dimethylpropyl)amino)-2-hydroxypropoxy)phenyl)-3-phenyl- but more generally known as diprafenone, which bears US NIH Compound Identifier 71249. European Medicines Agency schedules Diprafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07219MIG.

UNSPSC 51123904 Diprafenone, a Commodity code, covers cardiac and emergency-response medications supplied to state and local government agencies, though recent solicitations show activity across a broader range of advanced life support drugs than diprafenone alone. State and local buyers under this code include municipal fire-rescue departments, state health and human services commissions, and cooperative purchasing alliances representing multi-state and multi-jurisdictional government entities. The scope of work involves supplying FDA-compliant pharmaceuticals with specified National Drug Codes, maintaining expiration dates of nine months to one year from delivery, arranging logistics and cold-chain management where required, and providing comprehensive safety documentation including Safety Data Sheets and accessibility conformance reports. Vendors must hold commercial general liability and professional liability insurance, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintain relationships with authorized wholesalers or direct-distribution channels.

Recent activity spans Florida, Texas, and Minnesota-led cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue, with a due date of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent small local business enterprise bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit managers and group purchasing organizations, signaling intent to pilot new supply-chain arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; this cooperative vehicle serves state and local facilities across participating jurisdictions including Oregon.